BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis
Status:
Completed
Trial end date:
2017-11-15
Target enrollment:
Participant gender:
Summary
This study will be conducted to evaluate the therapeutic bioequivalence of a TEST formulation
of calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064% to
the RLD.